Published in Hum Gene Ther on August 01, 2008
Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol (2015) 1.24
Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev (2011) 1.12
Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther (2010) 1.07
Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One (2013) 1.05
Selecting the optimal cell for kidney regeneration: fetal, adult or reprogrammed stem cells. Organogenesis (2011) 0.98
Kallikrein transduced mesenchymal stem cells protect against anti-GBM disease and lupus nephritis by ameliorating inflammation and oxidative stress. PLoS One (2013) 0.95
Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells. Anesthesiology (2014) 0.94
Role of bone marrow-derived mesenchymal stem cells in a rat model of severe acute pancreatitis. World J Gastroenterol (2012) 0.94
Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. BMC Med (2015) 0.91
Mesenchymal stem cell treatment for chronic renal failure. Stem Cell Res Ther (2014) 0.91
Breast cancer biology: the multifaceted roles of mesenchymal stem cells. J Oncol (2008) 0.89
Transglutaminase-1 protects renal epithelial cells from hydrogen peroxide-induced apoptosis through activation of STAT3 and AKT signaling pathways. Am J Physiol Renal Physiol (2009) 0.87
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol (2010) 0.87
Potential advantages of acute kidney injury management by mesenchymal stem cells. World J Stem Cells (2014) 0.87
Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke. PLoS One (2015) 0.84
Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest (2013) 0.84
Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice. Mol Ther (2011) 0.82
14S,21R-dihydroxy-docosahexaenoic acid treatment enhances mesenchymal stem cell amelioration of renal ischemia/reperfusion injury. Stem Cells Dev (2011) 0.82
The regulation of inflammatory mediators in acute kidney injury via exogenous mesenchymal stem cells. Mediators Inflamm (2014) 0.82
Glutathione S-transferase Mu 2-transduced mesenchymal stem cells ameliorated anti-glomerular basement membrane antibody-induced glomerulonephritis by inhibiting oxidation and inflammation. Stem Cell Res Ther (2014) 0.82
Concise review: mesenchymal stem cell treatment for ischemic kidney disease. Stem Cells (2013) 0.82
Maximum efficacy of mesenchymal stem cells in rat model of renal ischemia-reperfusion injury: renal artery administration with optimal numbers. PLoS One (2014) 0.81
Histological study on effect of mesenchymal stem cell therapy on experimental renal injury induced by ischemia/reperfusion in male albino rat. Int J Stem Cells (2013) 0.81
The role of N-acetyltransferase 8 in mesenchymal stem cell-based therapy for liver ischemia/reperfusion injury in rats. PLoS One (2014) 0.79
Three-Dimensional Aggregates Enhance the Therapeutic Effects of Adipose Mesenchymal Stem Cells for Ischemia-Reperfusion Induced Kidney Injury in Rats. Stem Cells Int (2015) 0.79
Association of functional kallikrein-1 promoter polymorphisms and acute kidney injury: a case-control and longitudinal cohort study. Nephron Clin Pract (2013) 0.76
Magnetic resonance imaging of stem cell apoptosis in arthritic joints with a caspase activatable contrast agent. ACS Nano (2015) 0.76
MR Imaging of Stem Cell Transplants in Arthritic Joints. J Stem Cell Res Ther (2014) 0.75
Kallikrein-kinin in stem cell therapy. World J Stem Cells (2014) 0.75
Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol (2005) 18.76
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res (1994) 8.57
Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med (2003) 8.46
Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol (2005) 6.71
Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest (1996) 3.73
Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol (2007) 3.54
Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol (2005) 3.40
Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther (2006) 2.85
Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int (2007) 2.75
Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem (1983) 2.58
Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest (1999) 2.55
Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation (2003) 2.51
Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int (2005) 2.29
Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest (1992) 2.14
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Role of IL-1 in renal ischemic reperfusion injury. J Am Soc Nephrol (1998) 1.67
The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res (2006) 1.56
Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res (1995) 1.55
Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol (2006) 1.47
Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem (2004) 1.35
The dual personality of NO. Trends Pharmacol Sci (2000) 1.33
Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol (2005) 1.32
Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2007) 1.30
Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant (2006) 1.29
Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int (1995) 1.29
Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol (1998) 1.26
Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol (2003) 1.19
Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol (2000) 1.18
GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int (2003) 1.16
Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int (2002) 1.15
Redistribution of cytoplasmic VEGF to the basolateral aspect of renal tubular cells in ischemia-reperfusion injury. Kidney Int (2000) 1.10
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res (2006) 1.09
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension (2003) 1.05
Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther (2006) 1.04
Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2000) 0.98
Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med (2006) 0.96
Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension (2007) 0.93
Adenoviral gene transfer of eNOS: high-level expression in ex vivo expanded marrow stromal cells. Am J Physiol Cell Physiol (2003) 0.92
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail (2007) 0.90
Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. Am J Physiol (1996) 0.89
Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther (1998) 0.88
Biology of ischemic and toxic renal tubular cell injury: role of nitric oxide and the inflammatory response. Curr Opin Nephrol Hypertens (1998) 0.88
Role of peroxynitrite on cytoskeleton alterations and apoptosis in renal ischemia-reperfusion. Am J Physiol Renal Physiol (2007) 0.87
Bcl-X(L) translocation in renal tubular epithelial cells in vitro protects distal cells from oxidative stress. Kidney Int (2001) 0.87
The role of chemokines in the initiation and progression of renal disease. Kidney Int Suppl (1995) 0.86
Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int (2004) 0.85
Characterization of monoclonal and polyclonal antibodies to human tissue kallikrein. Hypertension (1986) 0.83
Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int (1998) 0.83
Stem cell gene therapy for chronic renal failure. Curr Gene Ther (2003) 0.80
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest Endosc (2006) 4.31
Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol (2002) 3.13
A phenylalanine in DGAT is a key determinant of oil content and composition in maize. Nat Genet (2008) 2.89
Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc (2009) 2.84
Sedation and anesthesia in GI endoscopy. Gastrointest Endosc (2008) 2.73
ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc (2006) 2.63
Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (2012) 2.44
Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg (2008) 2.29
Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem (2001) 2.22
Therapeutic Armamentarium for Stricturing Crohn's Disease: Medical Versus Endoscopic Versus Surgical Approaches. Inflamm Bowel Dis (2015) 2.13
G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin "outside-in" signaling. Science (2010) 2.09
Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc (2008) 2.08
Infection control during GI endoscopy. Gastrointest Endosc (2008) 2.07
Twenty-year-old stapled pouches for ulcerative colitis without evidence of rectal cancer: implications for surveillance strategy? Dis Colon Rectum (2014) 2.01
Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg (2013) 1.91
Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension (2006) 1.80
Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol (2003) 1.75
Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol (2002) 1.74
Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology (2010) 1.72
Esophageal dilation. Gastrointest Endosc (2006) 1.68
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res (2008) 1.67
Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann Surg (2014) 1.58
Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology (2004) 1.58
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood (2002) 1.54
The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut (2012) 1.51
Whole genome scan detects an allelic variant of fad2 associated with increased oleic acid levels in maize. Mol Genet Genomics (2007) 1.50
Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett (2006) 1.44
Dysplasia associated with Crohn's colitis: segmental colectomy or more extended resection? Ann Surg (2012) 1.43
Endoscopy by nonphysicians. Gastrointest Endosc (2009) 1.42
The presence of primary sclerosing cholangitis is protective for ileal pouch from Crohn's disease. Inflamm Bowel Dis (2013) 1.39
Preoperative Clostridium difficile infection is not associated with an increased risk for the infection in ileal pouch patients. Dig Dis Sci (2014) 1.39
ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc (2006) 1.36
Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem (2004) 1.35
Regulation of prostasin by aldosterone in the kidney. J Clin Invest (2002) 1.33
Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J Am Chem Soc (2002) 1.33
Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum (2005) 1.31
Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.29
The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc (2006) 1.28
Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension (2008) 1.28
The role of endoscopy in patients with chronic pancreatitis. Gastrointest Endosc (2006) 1.26
Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest (2008) 1.25
Modifications in endoscopic practice for pediatric patients. Gastrointest Endosc (2008) 1.25
Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther (2006) 1.23
Role of EUS. Gastrointest Endosc (2007) 1.23
Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol (2003) 1.20
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension (2008) 1.14
Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension (2010) 1.12
Chiral proton catalysis: enantioselective Brønsted acid catalyzed additions of nitroacetic acid derivatives as glycine equivalents. J Am Chem Soc (2007) 1.12
Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol (2010) 1.11
Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol (2012) 1.10
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem (2010) 1.10
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res (2006) 1.09
Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors. Am J Gastroenterol (2009) 1.09
Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem (2009) 1.09
Tissue kallikrein activation of the epithelial Na channel. Am J Physiol Renal Physiol (2012) 1.08
Role of endoscopy in the bariatric surgery patient. Gastrointest Endosc (2008) 1.08
MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumour Biol (2012) 1.07
Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease: pouch retention and implications of delayed diagnosis. Ann Surg (2008) 1.07
Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care (2013) 1.07
Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant (2006) 1.06
Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis (2009) 1.06
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension (2003) 1.05
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology (2010) 1.05
Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2003) 1.05
Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther (2006) 1.04
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Racial and socioeconomic disparities in nutrition behaviors: targeted interventions needed. J Nutr Educ Behav (2009) 1.04
YouTube and inflammatory bowel disease. J Crohns Colitis (2012) 1.04